Sun, Apr 20, 2014, 3:01 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Star Scientific, Inc. (CIGX) Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The tick-tock tool is not only poly-moniker but he copies and claims it as his!!!! LOL!!!!

  • Reply to

    Inflammation control

    by rightn0w Apr 18, 2014 10:59 AM
    frazier52@sbcglobal.net frazier52 4 hours ago Flag

    I have normal bp, no arthritis and during an eye exam Saturday a physician was shocked when I told him I am 62.

  • Reply to

    Inflammation control

    by rightn0w Apr 18, 2014 10:59 AM
    frazier52@sbcglobal.net frazier52 4 hours ago Flag

    Do you think cancer treatment works drum? Really...

  • Reply to

    Inflammation control

    by rightn0w Apr 18, 2014 10:59 AM

    Ok Frankie what are the facts. Prove me wrong. I am waiting for your response. Let's see who is smarter. Or are you a dimwitted big bag of wind.
    I bet you don't respond. Tough guy except when called out.
    Drum

  • Reply to

    Inflammation control

    by rightn0w Apr 18, 2014 10:59 AM

    It is nice to see even at this late stage that you are either ignorant of the facts or just a poor liar.

    Sentiment: Strong Buy

  • Reply to

    Inflammation control

    by rightn0w Apr 18, 2014 10:59 AM

    Could be very dangerous. Down regulation of the immune system by artificial means such as ABLOC could weaken immune system response to cancer thus exacerbating the disease.

    You would be crazy to take ABLOC with this risk. Most people know this. That is why sales are anemic. Only dimwits like this bored's longs buy it. Thank God they are in the minority. There is hope for the human race but it ain't Izoff.
    Sincerest regrets
    Drum

  • Reply to

    A more active lifestyle

    by rightn0w Apr 18, 2014 11:01 AM

    Like who? Freddie? He is compensated. Isner? Ditto and anyway he is a loser. Not a good image for ABLOC. Name an athlete other than compensated ones who use ABLOC. Top athletes here in Honolulu take Astaxanthin. Why are sales declining and in the toilet? Gotta be a good reason. It does not work for a broad spectrum of individuals. And it is very expensive. That is why I have suggested to Mooseface to drop the price to $9.99 per 1,000 pill bottle. May not make a profit at this level but will make it up in volume. LOL
    REGRETS
    DRUM

  • No. It is a cause of stupidity. It causes consumers to invest in an obvious scam called Star lead by a moose faced CMO( chief Molestation officer). Evidence? Jest read posts submitted by this bored' slings. I rest my case.
    Drum

  • Reply to

    ATTENTION Short Bashers

    by pharma_treasure Apr 18, 2014 2:52 PM

    Barfffff

  • Reply to

    from the hub

    by fjl1946 17 hours ago

    You r late to the party. Mullan is not now focused on ALZ. He said so at the CC. STAR WILL PURSUE AS YET UNNAMED PROJECTS. THIS APPEARS TO BE A STALLING TACTIC. They have no strategy and they are in a quandary as to what to do. The main focus is to keep this scam going as long as possible so Mullan et al can continue stealing comp, bennies, fees for lending out shares, etc. That is it.
    Sincerest regrets
    Drum

  • Reply to

    Testimony -- From Supplement-Geek

    by uptick77777 Apr 18, 2014 8:12 PM

    Why do you hate the truth so much? And I only bring the message as I am but a simple messenger. You know that testimonials carry absolutely zero scientific weight. We do not know this person. We do not know what concurrent medications she may be on. We have no way of knowing whether this is jest a placebo effect. We don't even know if she is a real person or a plant say like Izoff. Why should anyone believe you. You raise more questions than you answer.

  • Reply to

    Testimony -- From Supplement-Geek

    by uptick77777 Apr 18, 2014 8:12 PM

    Drum you miserable k--c--u--f !

    Go pound salt you dead beat.

    Sentiment: Strong Buy

  • kB pathway may be suitable targets for therapeutic approaches against Alzheimer’s disease"

    Article at Roskamp website:
    The Roskamp Institute, a not-for-profit research Institute, is dedicated to finding cure for neuropsychiatric disorder, with the emphasis on Alzheimer’s disease (AD). Current research at the Roskamp Institute is focused on dissecting the molecular biological pathways implicated in Alzheimer’s disease pathogenesis in order to develop therapeutic targets specific to Alzheimer’s disease etiology. Dr. Michael Mullan (Director of the Roskamp Institute) and Fiona Crawford (Associate director of the Roskamp Institute) were part of the original team that discovered a genetic error called “Swedish mutation” which results in overproduction of beta-amyloid (Abeta) by aberrant proteolytic processing of amyloid precursor protein (APP). This mutation now forms the bases of most mouse model of Alzheimer’s disease . Previously, the Roskamp Institute published an article in a prestigious scientific journal, Nature, showing that Abeta plays a normal role in vasoactive mechanisms but also plays a role in vascular abnormalities and neurodegeneration mediated by free radical. Subsequently, Dr. Daniel Paris, a senior scientist at the Roskamp Institute, discovered that the vasoactive effects of Abeta are partly mediated via a pro-inflammatory pathway and showed that this effect of Abeta on the vasculature can be blocked by inhibiting specific target molecules. In order to further understand the role of Abeta in the vasculature, Dr. Paris investigated the long term effect of Abeta on vascular homeostasis. He then discovered that at low doses, Abeta promotes angiogenesis, while at high doses, certain forms of Abeta peptides are anti-angiogenic. Collectively, these novel findings resulted in new therapeutic prospects for the treatment of Alzheimer’s disease as well as Cancer. Researchers at the Roskamp Institute also showed that the presence of functional CD40/CD40L signaling is essential for the full development of Alzheimer’s disease like pathology in transgenic mouse models of AD. In particular, it was demonstrated that accumulation of cerebral Abeta is reduced in transgenic mouse models of Alzheimer’s disease by genetically or pharmacologically reducing the availability of CD40 ligand to CD40. The Roskamp Institute investigators subsequently revealed that loss of functional CD40L diminishes both APP processing to Abeta and microglial activation in the brain (Original findings published in journals Science and Nature Neuroscience). CD40L activated pathways in the presence of Abeta appear to mediate both of these effects as well as the hyperphosphorylation of murine tau in vivo at epitopes analogous to those which precede tangle formation of human tau. More recently, Dr. Ghania Ait-Ghezala of the Roskamp Institute showed that CD40/CD40L interaction also affects APP via the NF-kB pathway. Using NF-kB inhibitors and SiRNAs to silence diverse elements of the NF-kB pathway, she demonstrated that reduction in levels of both pathological forms of Abeta. These results showed that CD40L stimulation may be a key component in Alzheimer’s disease pathology and that NF-kB pathway may be suitable targets for therapeutic approaches against Alzheimer’s disease . Another major focus of research at the Roskamp Institute includes Traumatic Brain Injury (TBI) Program headed by the Associate Director of the Roskamp Institute. Dr. Crawford and her Roskamp Institute team demonstrated an important relationship between apolipoprotein E (APOE) and memory following Traumatic Brain Injury . She demonstrated that in Veteran’s with Traumatic Brain Injury , memory performance was significantly worse in individuals who had at least one copy of APOE epsilon4 allele than those who did not. She had subsequently been funded through the Veteran’s Administration to further study the relationship between different forms of APOE in Traumatic Brain Injury with the emphasis on finding treatments for this devastating condition. Drs. Michael Mullan and Fiona Crawford also received funding by the Counterdrug Technology Assessment Center (CTAC) to evaluate the newly emerged genomics and proteomics technology and find biological markers of substance abuse. Recently, Dr. Crawford’s team showed that cocaine treatment of human progenitor neuronal cells results in increased oxidative stress (possibly mediated by inflammatory responses) which precedes cell death. Thus, these findings may have implications for the consequences of cocaine abuse in situations where antioxidant capacity is compromised, as in the aging brain.As evident here, the Roskamp Institute team has been a pioneer in many area of research in neuropsychiatric diseases and will continue to do so to find novel therapies for these disorders. Currently, a new clinical trial based on the discoveries made at the Roskamp Institute is underway to assess safety and efficacy of nilvadipine in treatment of Alzheimer’s disease. Through the generous support of Diane and Robert Roskamp, the Veteran’s Administration, the National Institutes of Health, CTAC and the Department of Defense, the Roskamp Institute will continue to provide potential avenues for novel therapeutic interventions for neuropsychiatric disorders. Roskamp Institute is actively involved in Gulf War Syndrome or Gulf War Illness Research. Specifically the scientists are studying the effect of gulf war agents like PB & Permethrin on biological pathways using model organisms. You can read more about the research and clinical trials at: Roskamp Institute News and Articles . To learn more about Dr. Michael Mullan Alzheimer Research please visit Michael Mullan Alzheimer Research Notes or Michael Mullan Alzheimers Information website"

    Sentiment: Strong Buy

  • Reply to

    ATTENTION Short Bashers

    by pharma_treasure Apr 18, 2014 2:52 PM

    "ObamaCare offers an exemption to those who regularly take Anatabloc"

    Great Idea Caped Crusader!
    So it shall be written
    So it shall be done!

  • Reply to

    MY FAVORITE LONGS

    by drummword Apr 19, 2014 2:33 AM
    frazier52@sbcglobal.net frazier52 21 hours ago Flag

    I must say drum. That is a catchy name.

  • Unfortunately, ABLOC sales have not been resurrected and are gone, dead and buried. Time to find another savior for your financial(and spiritual) well-being.
    Bless you my children and on this day don't lay too many eggs
    Drummie Bunnie

  • Reply to

    ATTENTION Short Bashers

    by pharma_treasure Apr 18, 2014 2:52 PM

    Another lie.

    The truth is that ObamaCare offers an exemption to those who regularly take Anatabloc.... it cures and/or prevents everything!

    Sentiment: Strong Sell

  • Plagerism in its finest--only the subject of the article is not and never will be about ABLOC!!!!

  • Reply to

    TOP TEN WISH LIST FOR EASTER

    by drummword Apr 18, 2014 12:46 AM

    So original. Where do you get your non-comedic material?

  • If you are thinking ABLOC is the answer that is extremely questionable.

STSI
0.7499+0.0105(+1.42%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.